(Q43033715)

English

Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin

scientific article published in March 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

author name string

Yuko Inoue

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Naoki Hiramatsu

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Tsugiko Oze

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Takayuki Yakushijin

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Kiyoshi Mochizuki

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Kazuto Fukuda

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Eiji Mita

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yoshimichi Haruna

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Atsuo Inoue

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yasuharu Imai

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Atsushi Hosui

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Takuya Miyagi

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yuichi Yoshida

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Tomohide Tatsumi

14

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Shinichi Kiso

15

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Tatsuya Kanto

16

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Akinori Kasahara

17

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Tetsuo Takehara

18

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Norio Hayashi

19

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Journal of Medical Virology

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

83

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

419-427

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

DDX3 DEAD-box RNA helicase is required for hepatitis C virus RNA replication

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon-α in vitro

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Proteasome activation by hepatitis C core protein is reversed by ethanol-induced oxidative stress

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Diagnosis, management, and treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress

1 reference

https://api.crossref.org/works/10.1002%2FJMV.21975

21 January 2018

Identifiers

10.1002/JMV.21975

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43033715&oldid=1978254398"